-
June 20, 2008
Approach enlists immune system to fight leukemia
CHICAGO (Reuters) - Leukemia patients may be able to avoid developing resistance to the drug Gleevec through a mathematical formula that predicts when they should receive an immune-boosting vaccine, researchers said on Thursday.
-
March 7, 2008
Cancer drug may harm the developing fetus
NEW YORK (Reuters Health) - The majority of women who become pregnant while taking the cancer drug Gleevec, usually for a type of blood cancer called chronic myeloid leukemia, will probably have a successful outcome. However, there is a substantial risk of serious fetal malformations, according to a study reported this week.
-
March 5, 2008
Cancer pill could affect women's fertility - report
BOSTON (Reuters) - Long-term use of the cancer pill Gleevec may produce fertility problems in women, Greek doctors reported on Wednesday.
-
December 11, 2007
Leukemia vaccine triples event-free survival
NEW YORK (Reuters Health) - A new leukemia vaccine under investigation extends patients' event-free survival by more than three-fold, from 2.4 month with convention treatment to 8.7 months, investigators at the University of Texas M. D. Anderson Cancer Center in Houston reported this week at the 49th annual meeting of the American Society of Hematology underway in Atlanta.
-
December 10, 2007
Experimental drug works in type of leukemia
NEW YORK (Reuters) - Cephalon Inc's experimental cancer drug Treanda was significantly more effective than a common chemotherapy agent in helping patients with chronic lymphocytic leukemia (CLL) who had not received prior treatment achieve remission, according to a late-stage study.
-
April 13, 2007
Gleevec keeps stomach tumor at bay: study
WASHINGTON (Reuters) - Gleevec, a once-a-day pill that has helped boost the survival rate for some leukemia patients, lowers the risk that a rare stomach cancer will come back by 70 percent, U.S. researchers reported on Thursday.